Head and Neck Neuroendocrine Carcinoma — Trials

Head and Neck Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 27
Recruiting: 10
Ph III recruiting: 1
Growth YoY: —
Industry share: 30%
Top sponsor: Eli Lilly and Company
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01298323	Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment	completed	Phase 3	205	SanofiINDUSTRY	20	Apr 17, 2026	clinicaltrials
NCT04211337	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531)	active not recruiting	Phase 3	291	Loxo Oncology, Inc.INDUSTRY